Try our Advanced Search for more refined results
February 23, 2023
Alger Capital Appreciation Fund et al v. Biomarin Pharmaceutical Inc et al
Case Number:
3:23-cv-00826
See also:
Court:
Nature of Suit:
Judge:
Firms
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
February 24, 2023
BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says
California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing and approval process, while at the same time selling off "uncharacteristically" large amounts of BioMarin stock at artificially inflated prices.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login